Share our website:
European Patients Academy
  Choose your language:  

What is EUPATI?

The European Patients’ Academy (EUPATI) is a pan-European Innovative Medicines Initiative ( project of 33 organizations, led by the European Patients’ Forum, with partners from patient organizations (the European Genetic Alliance, the European AIDS Treatment Group, and EURORDIS), universities and not-for-profit organisations, along with a number of European pharmaceutical companies.

We focus on education and training to increase the capacity and capability of patients to understand and contribute to medicines research and development and also improve the availability of objective, reliable, patient-friendly information for the public.

We launched the Patient Expert Training Course in October 2014 in English and we are launching a web-based educational toolbox, hosting educational material in English, Italian, Spanish, Polish, German, French and Russian from January 2016, aiming to reach patient advocates across Europe.

To find out more about the project, our aims, and achievements, please visit

*We do not educate about disease-specific issues or therapies, but about the process of medicines development in general. Indication-specific information or specific medicine interventions are beyond the scope of European Patients’ Academy and are the remit of health professionals as well as patient organisations.

Watch a video

Meet EUPATI Switzerland

Patient representatives

Hansruedi Voelkle, Positivrat Schweiz, President

Liz Isler, EUPATI Ambassador (Forum Lungenkrebs Schweiz)

Rosmarie Pfau, EUPATI Fellow (Ho/noho)

Estelle Jobson, EUPATI Fellow (Endo-Help), Communications Officer


Academic representatives

Marie Mi Bonde Hansen, Scientific Collaborator University Hospital Basel

Cristiana Sessa, Director Clinical Trial Unit, EOC Ticino

Caecilia Schmid, Scientific Coordinator, Swiss Clinical Trial Organisation, Secretary

Rosine Mucklow, Quality Manager, Swiss Clinical Trial Organisation, Secretary

Annette Magnin, Managing Director, Swiss Clinical Trial Organisation


Pharmaceutical Company representatives



EUPATI Ambassadors

Liz Isler, Forum Lungenkrebs Schweiz

Nicole Scobie, Zoe4life


EUPATI expert trainees (Fellows)

Peter Lack, Childhood Cancer Switzerland

Rosemarie Pfau, ho/noho - Schweizerische Patientenorganisation fuer Lymphombetroffene und Angehoerige)

Estelle Jobson, Endo-Help

Florian Klett, EULAR


Advisory Board

Cordula Landgraf, Head networking, Swissmedic (Swiss Agency for Therapeutic Products)

Florian Klett, EUPATI Fellow

Peter Lack, EUPATI Fellow

Daniela Gunz, healthbank innovation AG


Communication Support

Mark Baecher, Anina Rüger, LifeScience Communication

EUPATI Switzerland - the story

In 2013, the Positivrat Schweiz, the Patient Advocates for Cancer Research and Treatment (PACRT), the Swiss Clinical Trial Organisation (SCTO) and the University Hospital Basel (USB) created an informal network of stakeholders in Switzerland interested in medicines research and development and patient involvement. Shortly thereafter, the team began to collaborate closely with Swissmedic, the Swiss Agency for Therapeutic Products.

In 2014, representatives from other patient organisations and the pharmaceutical industry joined the network and together a first public event was organised in December in Bern around the challenges and opportunities for patient involvement in Switzerland, which was attended by over 50 patient representatives, academic researchers and pharmaceutical professionals. A follow up event took place in March 2015 in the French speaking part of Switzerland, which again attracted more than 50 interested local stakeholders.

With the aim to establish patient involvement in medicines research and development and in order to grow and sustain the partnership and their activities after the end of the EUPATI project in 2017, it was agreed that the informal network would need a formal (or legal) entity. On 3 February 2016 an event was held to launch the ‘EUPATI National Platform in Switzerland’, which received support from more than 60 founding members. Since then, we have also received support from stakeholders in Ticino who are interested in connecting Italian speaking partners with the EUPATI National Platform in Switzerland. On October 4, 2016 the National Platform became a legal entity in the form of an association under Swiss law – EUPATI CH.

The EUPATI National Platform in Switzerland includes four Swiss patient representatives who are Fellows of the 14-month EUPATI Patient Expert Training Course plus two patient representatives as our Ambassadors.

For more information please visit our news section or contact us (

EUPATI Switzerland – the future

Throughout 2016 and 2017, we hope that all national partners with an interest in patient involvement will join our new association – EUPATI CH – and together we will continue to grow the patient involvement conversation in our country. We would like to see patient, academic and industry representatives join with government officials, regulatory bodies, health technology assessment agencies, associations of doctors and nurses, medical journalists and many more to better include patients across the medicines R&D process.

To ensure Swiss patients are equipped to get involved, EUPATI CH will seek to spread the word about the EUPATI Toolbox available at, as well as support patients to adapt this material for their own training and learning purposes.

We will also engage with the EUPATI Patient Expert Training Course Fellows to identify opportunities for sharing course material at the national level and for putting into practice the knowledge of medicines R&D gained during the course.

In 2017, we will also continue cooperation with research and industry, and we will organise joint events with key national partners in these sectors to explore how to increase the number of involvement initiatives and how to effectively encourage and replicate good practice.

Become a member of EUPATI Switzerland!

Receive invitations to EUPATI Switzerland events; learn about free patient education tools; and make new connections with patient involvement partners.